175 related articles for article (PubMed ID: 10563526)
1. Current and evolving therapies for hepatitis C.
Moradpour D; Blum HE
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1199-202. PubMed ID: 10563526
[TBL] [Abstract][Full Text] [Related]
2. [Hepatitis C].
Moradpour D; Blum HE
Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C: a concise review.
Moradpour D; Wölk B; Cerny A; Heim MH; Blum HE
Minerva Med; 2001 Oct; 92(5):329-39. PubMed ID: 11675577
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C: therapeutic perspectives.
Cornberg M; Wedemeyer H; Manns MP
Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
[TBL] [Abstract][Full Text] [Related]
5. Future trends in managing hepatitis C.
McHutchison JG; Dev AT
Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S51-61. PubMed ID: 15081103
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
7. New drugs for hepatitis C virus (HCV).
Clarke BE
Baillieres Best Pract Res Clin Gastroenterol; 2000 Apr; 14(2):293-305. PubMed ID: 10890323
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of hepatitis C].
Moradpour D; Blum HE
Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
[TBL] [Abstract][Full Text] [Related]
9. [Characteristics of the hepatitis C virus and viral predictors of therapeutic response].
Ambrosch A; König W
Med Klin (Munich); 1999 Nov; 94(11):626-32. PubMed ID: 10603734
[TBL] [Abstract][Full Text] [Related]
10. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
11. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
Main J
J Hepatol; 1995; 23 Suppl 2():32-5; discussion 35-6. PubMed ID: 8720292
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of hepatitis C virus infection].
Zeuzem S
Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
[TBL] [Abstract][Full Text] [Related]
13. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
Aghemo A; Rumi MG; Colombo M
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
[TBL] [Abstract][Full Text] [Related]
14. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
15. Investigational drugs for hepatitis C.
Flisiak R; Parfieniuk A
Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
[TBL] [Abstract][Full Text] [Related]
17. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
[TBL] [Abstract][Full Text] [Related]
18. [Molecular virology of hepatitis C].
Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
Praxis (Bern 1994); 2002 Dec; 91(51-52):2247-53. PubMed ID: 12564041
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of interleukin-8 in hepatitis C virus infection: relation to combined peg-interferon ribavirin response and genotype 4.
El Sayed ZM; Mansour FA; Ghal MF; Abou-Zahra SB
Immunol Invest; 2011; 40(1):29-38. PubMed ID: 20809700
[TBL] [Abstract][Full Text] [Related]
20. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
